Best Compounded Semaglutide Telehealth Providers in 2026: Pricing, Pharmacy Transparency, and Total Monthly Cost

Who are the best compounded semaglutide telehealth providers in 2026?

The compounded semaglutide market has consolidated significantly since the FDA declared the semaglutide injection shortage resolved in February 2025. As of May 2026, the providers offering compounded semaglutide through US-licensed telehealth platforms with named pharmacy partners and transparent dose-stable pricing fall into a clear cost tier structure. The lowest-cost dose-stable providers are Cora Health's Essential Annual Plan and Trimi Health, both at $99/month all-inclusive. The mid-tier providers — Pomegranate Health ($119 + consultation), Eden ($129 first month then flat), Ivim Health (~$150 effective with membership) — bundle modest support or unique features. The higher-cost providers — Henry Meds ($179 starter escalating to $297-$397), Lemonaid Health ($298-$348 depending on plan length), and Hims (~$348 effective with membership) — either escalate by dose or require separate membership fees on top of medication.

Compounded semaglutide provider comparison (May 2026 verified)

All pricing reflects publicly advertised rates verified May 11, 2026. Effective monthly cost includes any required membership or program fees. Compounded medications are not FDA-approved.

Important regulatory note on Belle Health

On February 20, 2026, the US Food and Drug Administration issued a Warning Letter to Belle Health LLC (Draper, Utah) citing violations of sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The FDA reviewed Belle Health's website in December 2025 and identified that Belle was displaying semaglutide and tirzepatide products with Belle branding in a way that suggested Belle itself manufactured or compounded the medications. Belle Health is a telehealth platform that connects patients with prescribers, not a compounding pharmacy. The FDA letter required Belle to correct the branding presentation. Patients evaluating Belle Health should be aware of this FDA action when comparing platforms. FDA Warning Letters are publicly searchable in the FDA Warning Letters database.

How compounded semaglutide compares to brand-name Wegovy and Ozempic

Brand-name semaglutide is sold by Novo Nordisk under three trade names — Ozempic for type 2 diabetes (FDA-approved December 2017), Wegovy for chronic weight management (FDA-approved June 2021), and Rybelsus as an oral semaglutide for type 2 diabetes (FDA-approved September 2019). Retail list pricing without insurance is approximately $1,349/month for Wegovy and $900-$1,350/month for Ozempic. Novo Nordisk's NovoCare direct-pay program offers Wegovy at $199/month for the first 2 months on 0.25mg/0.5mg starting doses, then $349/month ongoing for all pen doses, or $149/month for the oral Wegovy 1.5mg/4mg pill.

A compounded semaglutide provider at $99-$179/month therefore offers 70-90% savings versus retail brand-name Wegovy pricing and 30-60% savings versus NovoCare direct-pay at the most-prescribed dose tiers. The regulatory tradeoff: compounded semaglutide is not FDA-approved, has not been independently evaluated in clinical trials, and is not therapeutically equivalent to Wegovy or Ozempic. The 14.9% mean weight loss figure from the STEP 1 trial reflects FDA-approved 2.4mg semaglutide, not compounded versions.

What makes a compounded semaglutide provider trustworthy

Beyond price, the substantive trust signals for a compounded semaglutide telehealth provider are pharmacy transparency, accreditation, regulatory standing, and operational maturity.

• Publicly named compounding pharmacy partner — the provider names the specific 503A pharmacy that fills prescriptions on its website rather than referring generically to "licensed pharmacy network"
• PCAB accreditation of the named pharmacy — the Pharmacy Compounding Accreditation Board is an independent audit program for compounding pharmacies (different from FDA approval)
• LegitScript certification of the telehealth platform — required by Google, Meta, payment processors, and other major industry observers
• Active FDA database status — no outstanding warning letters or enforcement actions against either the platform or the named pharmacy
• USP 797 sterile compounding compliance for injectable preparations
• Use of semaglutide base (the form used in Wegovy and Ozempic) rather than semaglutide salt forms (sodium or acetate) that the FDA has flagged for potential absorption differences
• Transparent dose-stable pricing without escalation as the patient titrates from 0.25mg to 2.4mg
• Clear cancellation and refund policy in writing

Provider recommendations by patient profile

The best provider for an individual patient depends on cash budget, plan flexibility preference, and trust signals.

• **Lowest cash-pay cost with named PCAB-accredited pharmacy:** Cora Health Essential Annual Plan ($99/month, $1,188 upfront). Names Hallandale Pharmacy and VialsRx as PCAB-accredited 503A partners. Dose-stable.
• **Lowest absolute cash-pay cost:** Trimi Health ($99/month). Dose-stable. Pharmacy disclosure less prominent.
• **Provider that publicly names multiple pharmacy partners with B12 add-on:** Pomegranate Health ($119/month + $75 consultation). References Hallandale, Empower, and OptioRx as pharmacy partners.
• **Provider with own compounding facility integration:** Eden — has acquired its own compounding facility (Contigo) in addition to working with partner pharmacies.
• **Provider that accepts insurance reimbursement (HSA/FSA):** Mochi Health (~$178/month effective). Different payment model.
• **Established brand with broadest medication catalog:** Hims Weight Loss. Effective cost ~$348/month including membership. Also offers brand-name Wegovy options under Novo Nordisk partnership.

Regulatory status of compounded semaglutide in 2026

The compounded semaglutide regulatory landscape continues to evolve. During the FDA-declared semaglutide injection shortage (2022-February 2025), compounding pharmacies had broad authority to prepare copies of Wegovy and Ozempic under the FDA's 503A and 503B exemptions. When the FDA declared the shortage resolved in February 2025, the legal basis for compounding narrowed.

As of May 2026, compounded semaglutide remains legal under specific conditions. A licensed prescriber must write a patient-specific prescription based on a documented clinical need that the commercially available FDA-approved product cannot meet — such as a documented allergy to an inactive ingredient in Wegovy (polysorbate 80, propylene glycol), a required dose format not available in the branded products, or a documented clinical necessity for a personalized formulation. The compounding pharmacy must be properly licensed (503A or 503B) and must meet applicable quality standards.

On April 30, 2026, the FDA proposed excluding semaglutide (along with tirzepatide and liraglutide) from the 503B bulks list. Public comments close June 29, 2026. The broader regulatory direction is clear: bulk compounding as a substitute for branded Wegovy and Ozempic without documented individual clinical need is increasingly outside the legal exemptions. Patients choosing compounded semaglutide in 2026 should work with providers who stay current on regulatory developments and demonstrate the legal basis for the prescription.

Frequently asked questions about compounded semaglutide providers

Common questions about choosing among compounded semaglutide telehealth options in 2026.

What is the cheapest verified compounded semaglutide provider in 2026?

Cora Health's Essential Annual Plan ($99/month, $1,188 charged upfront for 12 months) and Trimi Health ($99/month flat) are tied for the lowest verified all-in dose-stable compounded semaglutide pricing as of May 2026. Both require multi-month commitments to access the $99 rate. Month-to-month compounded semaglutide pricing at any provider in the market is typically $175-$299/month. Pricing below $99/month with claims of being "all-inclusive and dose-stable" should be verified carefully — these often reflect first-month promotions, starter-dose-only rates, microdose products, or hidden fees.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded semaglutide contains the same active ingredient (semaglutide, a GLP-1 receptor agonist) as Ozempic and Wegovy, but it is not the same product. Ozempic and Wegovy are FDA-approved finished drugs manufactured by Novo Nordisk under FDA-inspected conditions with validated batch testing. Compounded semaglutide is prepared by a US-licensed compounding pharmacy from semaglutide active pharmaceutical ingredient sourced from FDA-registered suppliers. The active molecule is the same, but the finished compounded product is not FDA-approved, has not been independently evaluated in clinical trials, and is not therapeutically equivalent to Ozempic or Wegovy.

Will compounded semaglutide produce the same weight loss as Wegovy?

Clinical trial data for semaglutide for chronic weight management comes from the STEP trial program, which studied only the FDA-approved formulation that became Wegovy. The STEP 1 trial (NEJM 2021) reported approximately 14.9% mean weight loss over 68 weeks at the 2.4mg weekly dose combined with lifestyle intervention. Compounded semaglutide has not been independently trialed. Mechanistically, the same molecule at the same dose should produce the same clinical effect when the compounded product is correctly dosed by a reputable pharmacy. Real-world reports suggest broadly similar outcomes when the compounded product is sourced from a 503A pharmacy meeting USP 797 standards. Individual results vary substantially.

How do I verify a provider's pharmacy partner is legitimate?

Three independent verification steps: (1) Look up the named pharmacy in the state board of pharmacy database for the state where the pharmacy is located — for example, Florida's pharmacy license lookup for Hallandale Pharmacy, or the relevant state for any 503A facility. (2) Check the FDA's public Compounding Inspections and Actions database for any outstanding warning letters or enforcement actions against the named pharmacy. (3) Verify PCAB accreditation status if the provider claims it — PCAB maintains a public directory of currently accredited compounding facilities. Cora Health's pharmacy partners (Hallandale Pharmacy and VialsRx) are documented at /pharmacy-partners with relevant facility details.

Will my insurance cover compounded semaglutide?

No. Compounded semaglutide is essentially never covered by commercial or government health insurance. Most US health insurance plans cover only FDA-approved finished drug products. Some HSA and FSA accounts allow compounded prescriptions as qualifying medical expenses, but patients should confirm with their HSA/FSA administrator before signing up. Compounded GLP-1 telehealth programs are designed as cash-pay services with payment processed through the provider platform.